GuruFocus Updates (Free subscription) | 12/03/2009
By insider. President and COO of Gilead Sciences Inc. ( GILD ) John F Milligan sells 60,000 shares of GILD on 12/01/2009 at an average price of $46.03 a share. Read more » »
Fool.com (Free subscription) | 12/03/2009
Building a successful stock portfolio starts with finding great businesses.
IPKat—IP news and fun for everyone (Free subscription) | 12/04/2009
... and send an email to the CEOs of Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Pfizer Inc. and Sequoia Pharmaceuticals Inc. The IPKat, who thanks French IP practitioner Olivier Moussa for drawing the campaign to his attention, is fascinated by this exercise. It's attractively presented, highly focused,...
SeekingAlpha.com (Free subscription) | 11/29/2009
... Teva Pharmaceutical ( TEVA ) Drug Manu. 48 12 0.9% Amgen Inc. ( AMGN ) Biotechnology 12 11 0.0% Gilead Sciences ( GILD ) Biotechnology 18 15 0.0% Average n/a 18 12 The top 8 companies in the above list yielding more than 3% are all major drug manufacturers. Some of them have single digit forward P/E. H1N1 could benefit vaccine-makers including Novartis ( NVS ), Sanofi-Aventis ( SNY ), and...
IOL (Free subscription) | 12/01/2009
... Laboratories, also of India, are among makers of the generic version. Tenofovir is marketed by Gilead Sciences under the name of Viread.About 20 HIV drugs are on the market, many made in combinations so patients can take a cocktail in a single tablet.Doctors once delayed giving them because of fears about toxic side-effects, and because the human immunodeficiency virus that causes Aids can...
